Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty® System and Enrollment of First Patient in DISRUPT PAD III Global Clinical Trial

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Novel Technology Uses Sonic Pressure Waves to Treat Peripheral Artery Blockages

Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced two milestones for its Lithoplasty® System for the treatment of calcified plaque in patients with peripheral artery disease (PAD): enrollment of the first patient in the global DISRUPT PAD III clinical trial at the Medical University of Graz, Austria, and the treatment of the first patient in a commercial case in the United States, at Pottstown Memorial Medical Center in Pottstown, Pa.

The Lithoplasty System is an innovative therapy designed to treat calcified leg artery blockages with lithotripsy, sonic pressure waves historically used to treat patients with kidney stones. The technology is now commercially available in both the United States and Europe for the treatment of calcified plaque in peripheral arteries.

DISRUPT PAD III is the largest ever multi-center randomized trial to exclusively enroll patients with heavily calcified PAD. The objective of the post-market trial is to assess the optimal therapy to dilate heavily calcified lesions by comparing the Shockwave Medical Lithoplasty System versus traditional angioplasty, with a primary goal of achieving less than 30 percent residual stenosis without the need for stenting. In addition, all patients who do not receive a stent will be treated with a drug-coated balloon. The trial will enroll 334 patients in up to 45 global sites.

Marianne Brodmann, M.D., of the Medical University of Graz, Austria, enrolled the first patient in the trial.

Prof. Bodmann, said, “I’m pleased to be taking part in this important study of the Lithoplasty System for the treatment of complex peripheral artery disease.”  “Patients with challenging heavily calcified PAD have been excluded from previous drug coated balloon trials. The results of the DISRUPT PAD III randomized trial will bear important implications for treatment of this very important patient population,” notes Prof. Bodmann.

Vascular Surgeon, Edward Pavillard, D.O., at Pottstown Memorial Medical Center, used the Lithoplasty System to treat a patient with PAD in the first commercial U.S. case.

“Peripheral artery disease is a common, painful and possibly limb threatening disease that can be challenging to treat,” Dr. Pavillard said. “Calcified plaque has long been an Achilles heel for many endovascular interventions. The Lithoplasty System is a significant advancement in the treatment of PAD, as it provides a new treatment option with potentially less risk of damage or injury to the vessel. I am excited to be among the first in the United States to use this technology to help restore blood flow and improve the quality of life for my patients with complex, traditionally difficult to treat peripheral lesions.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles